"I am very pleased to be nominated to Sangamo's board of directors," commented Mr. Wiggans. "Sangamo is establishing an important new therapeutic product development platform based on their proprietary ZFP technology. This is an exciting stage for the company as they prepare to present their first Phase 2 data from their lead ZFP Therapeutic(TM) program in diabetic neuropathy. I look forward to contributing my operational experience to help position Sangamo for future growth and success."
Mr. Wiggans will be eligible for election to the board at Sangamo's 2008 Annual Meeting when existing board members will also be under consideration for re-election by shareholders. The meeting will be held at 9:00 am (PT) on Wednesday, June 4, 2008 at the company's headquarters in Richmond, California.
Important Additional Information Filed with the SEC
Sangamo and its directors and officers may be deemed to be participants in the solicitation of proxies in connection with Sangamo's 2008 Annual Meeting of Stockholders. Sangamo will file with the SEC and mail to its stockholders definitive proxy statement for the Annual Meeting of Stockholders. The definitive proxy statement will contain important information regarding the participants in the solicitation and proposals submitted to the stockholders for approval at the Annual Meeting, including the proposal to elect directors of Sangamo.
Stockholders of Sangamo are advised to read the definitive proxy
statement when it becomes available. Stockholders of Sangamo may obtain,
free of charge once they become available, copies of the definitive proxy
statement and other documents filed by Sangamo with the SEC at the internet
website maintained by the SEC at http://www.sec.gov. These documents
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved